New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
06:37 EDTALXNAlexion granted ODD to Soliris by FDA
Alexion Pharmaceuticals announced that the FDA has granted an orphan drug designation, or ODD, to Soliris, a first-in-class terminal complement inhibitor, for the prevention of delayed graft function, or DGF in renal transplant patients. DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
06:34 EDTALXNAlexion cuts FY!5 non-GAAP EPS to $4.70-$4.80 from $5.60-$5.80, consensus $4.98
Subscribe for More Information
06:32 EDTALXNAlexion reports Q2 Soliris sales $635.98M
Subscribe for More Information
06:32 EDTALXNAlexion reports Q2 non-GAAP EPS $1.44, consensus $1.38
Subscribe for More Information
July 29, 2015
15:08 EDTALXNNotable companies reporting before tomorrow's open
Subscribe for More Information
July 28, 2015
07:20 EDTALXNBrookings Institute to hold a public meeting
Subscribe for More Information
July 27, 2015
08:38 EDTALXNAnalysts divided on Biogen following $85 selloff
Subscribe for More Information
06:28 EDTALXNAlexion resumed with an Overweight at JPMorgan
Target $249.
July 22, 2015
09:28 EDTALXNBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
July 21, 2015
07:05 EDTALXNOphthotech names Shima as Chief Scientific Officer, Bjarke as CCO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use